Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nathan Nachlas

Facial Plastic Surgery Boca Raton, FL Medical Doctor

NPI 1497737647 CMS profile 719124

1601 Clint Moore Rd Ste 170, Boca Raton, FL 33487

Open in the dashboard

General payments

$5,127

151 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$498,534 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Nathan Nachlas of Boca Raton, FL is reported in the CMS Open Payments database as having received $5,127 across 151 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $498,534 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $535 18
2024 General $1,047 24
2023 General $506 17
2022 General $551 17
2021 General $616 13
2020 General $460 17
2019 General $1,412 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Nachlas
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Nathan Nachlas were reported at $535. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Nathan Nachlas Facial Plastic Surgery median Middle half National median
2019 $1,412 $225 $92–$651 $163
2020 $460 $132 $45–$323 $114
2021 $616 $186 $67–$558 $132
2022 $551 $218 $83–$594 $149
2023 $506 $237 $94–$564 $160
2024 $1,047 $233 $104–$575 $164
2025 $535 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acclarent, Inc $900 26 payments
  2. OptiNose US, Inc. $699 25 payments
  3. Inspire Medical Systems, Inc. $479 8 payments
  4. Aerin Medical Inc. $474 15 payments
  5. Intersect ENT, Inc. $473 10 payments
  6. Regeneron Healthcare Solutions, Inc. $341 13 payments
  7. Genzyme Corporation $294 10 payments
  8. Stryker Corporation $291 5 payments
  9. GlaxoSmithKline, LLC. $225 11 payments
  10. AstraZeneca Pharmaceuticals LP $158 3 payments
  11. Other $792 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,028 149 payments
  2. Gift $51 1 payment
  3. Education $48 1 payment
Products named General payments · program years 2019–2025
  1. Xhance $699 25 payments
  2. INSPIRE $479 8 payments
  3. Vivaer RF Stylus $468 14 payments
  4. TruDi $427 15 payments
  5. PROPEL $335 4 payments
  6. DUPIXENT Inflammation And Immunology $315 12 payments
  7. DUPIXENT Immunology $281 9 payments
  8. NUCALA $201 10 payments
  9. RELIEVA SpinPlus NAV Balloon Sinusplasty System $160 4 payments
  10. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $145 1 payment
  11. Other $2,118 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

457

Median for Otolaryngology: 297

Drug cost

$9,216

Median for Otolaryngology: $6,314

Branded share of claims

5%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 136 $4,094
Azelastine Hcl Generic 110 $3,141
Montelukast Sodium Generic 82 $636
Fluticasone Propionate Generic 37 $526
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 23 $253
Doxycycline Monohydrate Generic 26 $241
Methylprednisolone Generic 25 $220
Mupirocin Generic 18 $106

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$273,059

Of which drugs: $73

Medicare patients

295

Average age 75

Services billed

2,989

163 women, 132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 61%
Ischemic heart disease 45%
Osteoporosis 27%
Diabetes 26%
Depression 22%
Chronic kidney disease 20%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 96 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $153
  • GENZYME CORPORATION $107
$260 — —
Xhance
  • OptiNose US, Inc. $234
$234 — —
NUCALA
  • GlaxoSmithKline, LLC. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record